Company Profile
MannKind Stock Price, News & Analysis
- Ticker:
- MNKD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.89 USD (-5.12%)
Close
Last updated: August 6, 2026
1.06B USD
Market cap
Why the stock is moving
Following the latest company update, “MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update”, MNKD closed down 5.12% at $3.89 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Inhaled Drug Delivery
MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery.
Commercial Portfolio
Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid overload outside traditional infusion settings.
MNKD-201
MNKD-201 is an inhaled dry-powder formulation of nintedanib being advanced for idiopathic pulmonary fibrosis through the INFLO clinical program.
Ralinepag DPI
MNKD-1501 is an inhaled ralinepag program being developed with United Therapeutics for pulmonary hypertension.
Orphan-Lung Pipeline
MannKind is applying its pulmonary-delivery expertise to additional orphan lung diseases, including conditions that currently require prolonged multidrug treatment.
Future catalysts
First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
FDA action on the pediatric Afrezza indication by May 29, 2026.
FDA action on the FUROSCIX ReadyFlow autoinjector by July 26, 2026.
Topline Phase 1b INFLO-1 data for MNKD-201 in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
MannKind Announces $50 Million Private Placement
Source: MannKind
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MannKind (MNKD)?
MannKind (MNKD) most recently closed at 3.89 USD, a -5.12% move versus the previous session.
What is the market cap of MannKind (MNKD)?
MannKind currently has a market capitalization of 1.06B USD on BioPharmSignal.
What does MannKind do?
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid overload outside...
On which exchange is MNKD stock listed?
MannKind (MNKD) is associated with NASDAQ, United States, Biopharma.
What is MNKD-201?
First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
Which conditions is MannKind targeting with MNKD-201?
First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
How does MannKind describe recent progress with MNKD-201?
First patient enrollment in the Phase 2 INFLO-2 study of MNKD-201 in the second quarter of 2026.
What is MNKD-1501?
Ralinepag DPI MNKD-1501 is an inhaled ralinepag program being developed with United Therapeutics for pulmonary hypertension.